This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): AMG 103, blinatumomab, MEDI538, MEDI-538, MT103, MT 103
Description: MT103 represents a new class of therapeutics that may be capable of instructing the patients' own T cells (a very potent type of killer cell) to repeatedly eliminate tumor cells. This technology is called BiTE (bispecific T cell engager). MT103 binds to the cell surface antigen CD19 on leukemic B cells and to CD3 on T-cells.
Micromet and MedImmune
In June 2003, MedImmune announced an agreement to jointly develop Micromets MT103. Under the terms of the agreement, Micromet will receive milestone payments based on the successful development, filing, registration and marketing of MT103, as well as royalties on MedImmunes North American sales of the product. Furthermore, MedImmune Ventures, Inc., a wholly owned venture capital subsidiary of MedImmune, will make an investment in Micromet. MedImmune receives Micromets product rights to MT103 in North America and will assume responsibility for clinical development, registration and commercialization of the product in that region. As part of the agreement, MedImmune will develop the commercial manufacturing process and supply clinical trial material as well as commercial products for all markets. Micromet retains rights to MT103 outside of North America.
AstraZeneca and MedImmune
In June 2007, AstraZeneca closed its acquisition of...See full deal structure in Biomedtracker
Partners: AstraZeneca PLC Astellas Pharma, Inc. Dr. Reddy's Laboratories
Pink Sheet Ocrevus Tries Again For EU Approval Nod
Additional information available to subscribers only: